RA
VIR icon

Royce & Associates’s Vir Biotechnology VIR Stock Holding History

Royce & Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-102,900
Closed -$916K – 912
2024
Q2 		$916K Hold
102,900
– – 0.01% 727
2024
Q1 		$1.04M Hold
102,900
– – 0.01% 720
2023
Q4 		$1.04M Hold
102,900
– – 0.01% 735
2023
Q3 		$964K Sell
102,900
-4,923
-5% -$70.2K 0.01% 744
2023
Q2 		$2.64M Buy
107,823
+56,516
+110% +$1.42M 0.03% 628
2023
Q1 		$1.19M Sell
51,307
-5,596
-10% -$143K 0.01% 740
2022
Q4 		$1.44M Buy
56,903
+28,595
+101% +$701K 0.02% 697
2022
Q3 		$546K Buy
+28,308
New +$720K 0.01% 807

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return